SEOUL, Nov. 20 (Korea Bizwire) — Samsung Biologics Co. said Wednesday it has won two new contract manufacturing deals with a combined value of 930.4 billion won (US$667.7 million) from a Europe-based biopharmaceutical firm. The deals, set to last until the end of 2031, are valued at 752.4 billion won and 178 billion won, respectively, [...]
SEOUL, Oct. 22 (Korea Bizwire) — Samsung Biologics Co. said Tuesday it has signed a deal worth US$1.24 billion for contract manufacturing from an Asia-based biopharmaceutical firm. The deal will last until the end of 2037, the company said in a regulatory filing. Other details remained undisclosed under a confidentiality agreement. Samsung Biologics said the [...]
SAN DIEGO, Jun. 4 (Korea Bizwire) – Samsung Biologics, a leading biopharmaceutical company, has unveiled a new platform and customized brand to strengthen its contract development and manufacturing organization (CDMO) capabilities in the biotech drug development arena. At the 2024 BIO International Convention in San Diego, the company introduced its new CDMO platform, S-Tensify, designed to [...]
SEOUL, Jan. 31 (Korea Bizwire) –Samsung Biologics has disclosed that the total compensation package for its employees, including wages and benefits, can reach up to 100 million KRW annually for first-year employees. On January 31, it was revealed that Samsung Biologics had shared a “Total Compensation Statement” with its employees for the first time, detailing [...]
Companies share commitment to innovating quality control processes to meet biomanufacturing challenges such as scale, data integrity and accelerating time to market LOWELL, Mass., Jan. 04, 2024 (Korea Bizwire) – Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and [...]
SEOUL, July 10 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has signed a US$390.9 million deal with Novartis Pharma AG to manufacture the Switzerland-based pharmaceutical firm’s products. It is the final contract for an investment letter of intent announced in June last year, in which [...]
SEOUL, July 4 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has sealed a combined US$1.08 billion partnership contracts with U.S. pharmaceutical giant Pfizer so far this year. The Korean company said it signed a new contract with Pfizer, a follow-up to the bilateral deal set [...]
SEOUL, June 8 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Thursday it has signed a US$411.3 million contract with Pfizer to manufacture the U.S. pharmaceutical firm’s products. Under the deal with Pfizer, Samsung Biologics will manufacture Pfizer’s multi-product biosimilar portfolio, including oncology, inflammation and immunotherapy, at its [...]
SEOUL, June 6 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Tuesday it will move up the operation of its new biomedicine production facility by five months in a way to deal with rising demand. The company has invested 1.98 trillion won (US$1.51 billion) to build Plant 5 [...]
SEOUL, Jan. 28 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday its 2022 net income more than doubled on strong overseas sales of its biomedicine products after its takeover of Samsung Bioepis Co. Its net income reached 798.1 billion won (US$648.1 million) in 2022, up 102.8 percent [...]